This Weight Loss Stock is Still a Strong Buy

The obesity market opportunity is substantial [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, The obesity treatment boom just got a bit more explosive. Company: Viking Therapeutics (SYM: VKTX) Today, for example, Viking Therapeutics (SYM: VKTX) rocketed about $16 higher – and could easily see higher highs. All after the company announced it was speeding up the development of its weight loss pill. Better, as noted by Barron’s, “The shortened timeline for the clinical testing of the shot makes Viking an even more ripe target for one of the big pharma firms looking to snap up an obesity drug of their own.” --------------------------------------------------------------- Stansberry Research [5 Wall Street Legends Just Bought This One Stock]( "If you're not at the table, you're on the menu," says former Goldman Sachs VP, Dr. David Eifrig. [Get the full story here.]( --------------------------------------------------------------- Now, instead of moving into a mid-stage Phase 2b trial, which would confirm optimal dosing levels, it’s moving into Phase 3 to get closer to US FDA approval. “The company said that Food and Drug Administration guidance will require two Phase 3 trials and that it expects those trials to cost roughly $300 million.” With all of the excitement, we wouldn’t be shocked to see VKTX closer to $100 a share again. We also have to consider the obesity market opportunity is substantial. --------------------------------------------------------------- Eagle Research [URGENT WARNING: Millions Of Retirements Are At Risk]( Congress is spurring on the most dangerous retirement threat of the last 50 years. America’s top retirement researcher reveals the deadly truth behind this government move… Plus the ONLY way to fully protect your wealth in the coming months. [Click Here for the Full Story]( --------------------------------------------------------------- As noted by Goldman Sachs, the global obesity treatment market could grow to $130 billion by 2030. Even Morgan Stanley expects the global obesity drug treatment market to reach $105 billion by 2030 from $77 billion. At the high end, $144 billion. Plus, there may be no shortage of demand. That’s because, according to the World Health Organization, obesity has more than doubled since 1990. Adolescent obesity has quadrupled. In addition, about 390 million children and adolescents aged five to 19 years were overweight in 2022, including 160 million who were living with obesity. --------------------------------------------------------------- InvestorPlace [Aerial Footage of Jeff Bezos's Next Trillion Dollar Bet]( [ball](Located 30 miles from Baltimore — Jeff Bezos has been quietly investing in one tiny company that's ground zero of a tech revolution that's going to change everything. Bank of America said the technology would be, "Bigger than fire and bigger than all the revolutions that humanity has seen." [And for investors who get in now profits could be massive — click here for full story.]( --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you currently own any shares of weight-loss pharma stocks? Do you have your eye on any other under-the-radar pharma stocks we might have missed? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets](  [Unsubscribe]( Â